Trexquant Investment LP Acquires 92,843 Shares of AnaptysBio, Inc. $ANAB

Key Points

• Trexquant Investment LP increased its stake in AnaptysBio by 152.9% during the first quarter, owning 153,563 shares valued at approximately $2.86 million.
• Several other hedge funds also boosted their holdings in AnaptysBio, with increases ranging from 126.5% to 9,778.9% during the same period.
• AnaptysBio reported earnings of ($1.34) EPS, surpassing analysts' expectations, with revenue of $22.26 million for the quarter.

Trexquant Investment LP raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 152.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 153,563 shares of the biotechnology company's stock after acquiring an additional 92,843 shares during the quarter. Trexquant Investment LP owned approximately 0.52% of AnaptysBio worth $2,855,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in shares of AnaptysBio by 14.4% in the 1st quarter. Wellington Management Group LLP now owns 76,021 shares of the biotechnology company's stock worth $1,413,000 after buying an additional 9,554 shares during the last quarter. Brooklyn Investment Group raised its position in AnaptysBio by 1,779.9% in the 1st quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company's stock worth $118,000 after buying an additional 6,034 shares during the last quarter. Algert Global LLC purchased a new stake in AnaptysBio during the first quarter valued at approximately $202,000. Cresset Asset Management LLC bought a new position in shares of AnaptysBio in the first quarter worth approximately $272,000. Finally, Fox Run Management L.L.C. purchased a new position in AnaptysBio during the first quarter valued at $517,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and increased their target price for the company from $22.00 to $38.00 in a research report on Wednesday, June 4th. Guggenheim reiterated a "buy" rating and set a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. JPMorgan Chase & Co. boosted their price target on AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. UBS Group reissued a "neutral" rating and set a $20.00 target price (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. Finally, Wedbush boosted their price objective on AnaptysBio from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, AnaptysBio currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.13.

Insider Buying and Selling at AnaptysBio

In other news, Director Hollings Renton sold 20,925 shares of AnaptysBio stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the transaction, the director directly owned 4,965 shares of the company's stock, valued at $117,025.05. This trade represents a 80.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 33.50% of the stock is currently owned by company insiders.

AnaptysBio Trading Up 3.2%

Shares of AnaptysBio stock traded up $0.71 during trading hours on Monday, reaching $22.61. 158,663 shares of the company's stock were exchanged, compared to its average volume of 737,802. The firm has a market capitalization of $633.08 million, a price-to-earnings ratio of -4.99 and a beta of -0.19. The company has a fifty day moving average of $23.13 and a 200-day moving average of $20.94. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $40.70.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The business had revenue of $22.26 million during the quarter, compared to analyst estimates of $11.55 million. On average, equities research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.